Key result
The authors debate the clinical utility of galectin-3 as a biomarker for atrial fibrillation recurrence, noting that differing follow-up durations and patient comorbidities may explain inconsistent results across studies.
Why the study?
Do galectin-3 levels predict arrhythmia recurrences after catheter ablation in patients with atrial fibrillation?
Do galectin-3 levels predict arrhythmia recurrences after catheter ablation in patients with atrial fibrillation?
Answers are grounded in this paper and cite their sources.
The prognostic utility of galectin-3 for predicting AF recurrence after ablation remains debated, with follow-up duration and comorbidities identified as key potential confounders.
We read with interest the paper by Takemoto et al. [(1)][1], where the translational aspect of profibrotic biomarkers in atrial fibrillation (AF) is discussed. The authors showed higher intracardiac levels of galectin-3 in patients with persistent AF compared with paroxysmal AF as well as a
No takes yet. Share an insight, caveat, or question.
Kornej et al. (2016) conducted a letter in Atrial Fibrillation. Galectin-3 was evaluated. The authors debate the clinical utility of galectin-3 as a biomarker for atrial fibrillation recurrence, noting that differing follow-up durations and patient comorbidities may explain inconsistent results across studies.
Synapse has enriched 10 related papers. Consider them for comparative context: